<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163642</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-BRO-2013-154</org_study_id>
    <nct_id>NCT02163642</nct_id>
  </id_info>
  <brief_title>Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis</brief_title>
  <official_title>Bronchial Infections in Patients With Non-Cystic Fibrosis (CF) Bronchiectasis; Role of Innate Lung Defense Mechanisms and Utility of an Electronic Nose for Its Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that 1) the secretion of mucins, antimicrobial
      peptides and Toll-like receptors is altered in certain patients with non-CF bronchiectasis,
      which makes them more susceptible to be infected by potentially pathogenic bacteria (PPB);
      and 2) the electronic nose is able to detect patterns of specific Volatile Organic Compounds
      (VOC) for patients with non-CF bronchiectasis colonized by PPB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, observational study, which will include 50 patients with non-CF bronchiectasis
      who will be followed for a period of 12 months. A follow up control will be performed every
      three months to all patients, consisting in medical record, lung function tests, blood and
      serum collection, sputum analysis and culture, and collection of exhaled air for analysis
      using an electronic nose. These tests will also be repeated whenever the patient has an
      exacerbation. At the beginning and end of the study, a high resolution chest CT will be
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sputum mucin levels at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Mucin levels in sputum will be determined with ELISA kits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sputum mucin levels at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Mucin levels in sputum will be determined with ELISA kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sputum mucin levels at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Mucin levels in sputum will be determined with ELISA kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sputum mucin levels at 9 months</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Mucin levels in sputum will be determined with ELISA kits</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in patterns of specific volatile organic compounds in exhaled air at 3 months</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The patterns of specific volatile organic compounds in exhaled air will be determined with the electronic nose device (Cyranose® 320).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in patterns of specific volatile organic compounds in exhaled air at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The patterns of specific volatile organic compounds in exhaled air will be determined with the electronic nose device (Cyranose® 320).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in patterns of specific volatile organic compounds in exhaled air at 9 months</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>The patterns of specific volatile organic compounds in exhaled air will be determined with the electronic nose device (Cyranose® 320).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in patterns of specific volatile organic compounds in exhaled air at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The patterns of specific volatile organic compounds in exhaled air will be determined with the electronic nose device (Cyranose® 320).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Non-CF Bronchiectasis</arm_group_label>
    <description>Cyranose® 320</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cyranose® 320</intervention_name>
    <description>Detection of patterns of specific Volatile Organic Compounds in exhaled air</description>
    <arm_group_label>Non-CF Bronchiectasis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Serum samples

        -  Sputum samples and cultures
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of non-CF bronchiectasis will be recruited from the outpatient
        clinic of the Pneumology Service of the Sant Pau Hospital in Barcelona
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non- CF bronchiectasis based on at least 1 lobe with bronchial dilatation
             and compatible clinical symptoms such as cough, sputum production and respiratory
             infections.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Presence of exacerbation in the last 4 weeks.

          -  Antibiotic treatment in the last 4 weeks

          -  Use of oral corticosteroids in the last 4 weeks

          -  Concomitant terminal illness.

          -  Current cigarette smoking

          -  Active allergic bronchopulmonary aspergillosis

          -  Diagnosis of tuberculosis or active non-tuberculous Mycobacterial infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oriol Sibila, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriol Sibila, MD PhD</last_name>
    <phone>0034647914193</phone>
    <email>osibila@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Sibila, MD PhD</last_name>
      <phone>0034647914193</phone>
      <email>osibila@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Oriol Sibila, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>September 7, 2016</last_update_submitted>
  <last_update_submitted_qc>September 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>Immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

